ReGenTree Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • Joint Venture

  • Financing Rounds
  • 1

ReGenTree General Information

Description

Developer of RGN-259 for ophthalmic indications. The company conducts a phase 3 clinical trial for the orphan disorder, neurotrophic keratopathy (NK) and a 2b/3 dose-response, confirmatory trial for dry eye syndrome.

Contact Information

Website
www.regentreellc.com
Ownership Status
Privately Held (backing)
Financing Status
Corporate Backed or Acquired
Corporate Office
  • United States
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Corporate Office
  • United States

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

ReGenTree Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore ReGenTree‘s full profile, request access.

Request a free trial

ReGenTree Patents

  • 8

    Total Documents Applications and Grants

  • Total Patents Families

  • 4

    Granted

  • 3

    Pending

  • Expiring in next 12 mo

ReGenTree Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-3484497-A4 Methods of treating dry eye syndrome Pending 18-Jul-2016
US-20210213103-A1 Methods of treating dry eye syndrome Inactive 18-Jul-2016
EP-3484497-A1 Methods of treating dry eye syndrome Pending 18-Jul-2016
US-20190240294-A1 Methods of treating dry eye syndrome Active 18-Jul-2016
AU-2017300268-A1 Methods of treating dry eye syndrome Active 18-Jul-2016 A61K38/2292
To view ReGenTree’s complete patent history, request access »

ReGenTree Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore ReGenTree‘s full profile, request access.

Request a free trial

ReGenTree FAQs

  • When was ReGenTree founded?

    ReGenTree was founded in 2015.

  • Where is ReGenTree headquartered?

    ReGenTree is headquartered in .

  • What industry is ReGenTree in?

    ReGenTree’s primary industry is Drug Discovery.

  • Is ReGenTree a private or public company?

    ReGenTree is a Private company.

  • What is ReGenTree’s current revenue?

    The current revenue for ReGenTree is .

  • Who are ReGenTree’s investors?

    G-treeBNT and Regenerx have invested in ReGenTree.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »